CHANDRA BARTHOLOMEUSZ to Drug Resistance, Neoplasm
This is a "connection" page, showing publications CHANDRA BARTHOLOMEUSZ has written about Drug Resistance, Neoplasm.
Connection Strength
0.108
-
CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells. Breast Cancer Res Treat. 2015 Jun; 151(3):501-13.
Score: 0.046
-
Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res. 2007 Jun 15; 67(12):5779-88.
Score: 0.027
-
A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression. Breast Cancer Res Treat. 2014 Jul; 146(2):259-72.
Score: 0.011
-
Bisphosphorylated PEA-15 sensitizes ovarian cancer cells to paclitaxel by impairing the microtubule-destabilizing effect of SCLIP. Mol Cancer Ther. 2013 Jun; 12(6):1099-111.
Score: 0.010
-
Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. Mol Cancer Ther. 2008 Jul; 7(7):1846-50.
Score: 0.007
-
Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity. Mol Cancer Ther. 2007 Aug; 6(8):2168-77.
Score: 0.007